Immunotec Inc.

Immunotec Inc.

August 03, 2011 16:01 ET

Immunotec Appoints Mr. Daniel Audet as Vice-President of Marketing

MONTREAL, QUEBEC--(Marketwire - Aug. 3, 2011) - Immunotec Inc. (TSX VENTURE:IMM) ( a Canadian-based company and a leader in the wellness industry, today announces the appointment of Mr. Daniel Audet as Vice-President, Marketing.

"We are fortunate and proud to welcome Daniel to our team", said Stuart A. MacMillan, President. "As we continue to expand, his international experience and thorough knowledge of the North American markets will be invaluable."

Mr. Audet has over 20 years of experience in marketing, sales and corporate management with companies specializing in telecom, travel and nutrition, primarily in the network marketing industry. Most recently, he led a consulting team specializing in the development and launching of international direct marketing enterprises. Prior to this, he was Director of Sales and Marketing for Shaklee Corporation, where he developed sales and marketing tools and training for the company's independent distributors. He has also held several executive-level assignments for such companies as Fortune Hi-Tech Marketing Ltd., Excel Communications and Bell Canada.

Fluently bilingual and based in Montreal, Mr. Audet is a dynamic and results-oriented leader with a proven track record of developing and implementing creative sales and marketing strategies around the world.

About Immunotec Inc.

Immunotec is a network marketing company, offering a world-class business opportunity, supported by unique, scientifically-proven health products. Its cornerstone product, Immunocal®, is clinically proven to optimize the immune system. Headquartered near Montreal, Canada, the Company operates seamlessly in Canada, the United States, Mexico, the United Kingdom, Ireland and the Caribbean.

The TSX Venture does not accept responsibility for the adequacy or accuracy of this release.


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information

  • Patrick Montpetit
    VP and Chief Financial Officer
    (450) 510-4527